NEW YORK, Oct. 23, 2014 /PRNewswire/ -- Aethlon Medical Incorporated (OTCQB: AEMD) is a medical device company, focuses on creating devices for the treatment of cancer, infectious diseases, and other life-threatening conditions. It develops Aethlon Hemopurifier, a medical device that targets the elimination of circulating viruses and tumor-secreted exosomes that promote cancer progression. The company's Aethlon Hemopurifier is intended for the treatment of antiviral drug-resistance in hepatitis-C virus and human immunodeficiency virus infected individuals; serves as a countermeasure against viral pathogens not addressed by drug or vaccine therapies; and represents the therapeutic strategy to address cancer promoting exosomes. It also develops exosome-based products to diagnose and monitor cancer, infectious diseases, and neurological disorders; and is developing a medical device to reduce the incidence of sepsis in combat-injured soldiers. The company was founded in 1991 and is based in San Diego, California.
It's been almost a week since Aethlon Medical, Inc. announced that physicians at the Frankfurt University Hospital are using their Hemopurifier in an attempt to prevent the spread of the virus and boost the immune system of a Ugandan doctor who has contracted Ebola. As you probably know, the deadly disease is one of the hottest topics on the stock markets and, not surprisingly, the news had a major effect on AEMD's performance.
In a matter of just six and a half hours the ticker managed to gain as much as 66% and it even hit a 52-week high of more than $0.30 per share. Investors were extremely excited about the application of the blood filtration device and it wasn't long before some outfits and newsletters were also jumping up and down and waving their arms about. The general notion that the two outfits wanted to convey is that the use of AEMD's Hemopurifier in the battle against Ebola could open up numerous opportunities for the company.
An analyst brief which covers a brief technical analysis and analyst recommendation can be viewed in its entirety by using the link below. There is no cost obligation required to view this report:
http://bit.ly/-AEMD-AnalystReport
Copy and paste to browser may be required.
Forward-Looking Disclaimer
This report may contain certain forward-looking statements and information, as defined within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, and is subject to the Safe Harbor created by those sections. This material contains statements about expected future events and/or financial results that are forward-looking in nature and subject to risks and uncertainties. Such forward- looking statements by definition involve risks, uncertainties and other factors, which may cause the actual results, performance or achievements of mentioned company to be materially different from the statements made herein.
Not Financial Advice
BrokerBank Securities, Inc. make no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.
Compliance Procedure
Content is researched, written and reviewed on a best-effort basis by a 3rd party research analyst. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below. We do not engage in high frequency trading.
A full disclaimer can be found by viewing the analyst report.
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
BrokerBank Securities, Inc. is a member of the Financial Industry Regulatory Authority, CRD number #130116.
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/aethlon-medical-analyst-coverage-initiated-against-ebola-stock-crash-by-brokerbank-securities-inc-788427020.html
SOURCE BrokerBank Securities, Inc.
Advertisement
It's been almost a week since Aethlon Medical, Inc. announced that physicians at the Frankfurt University Hospital are using their Hemopurifier in an attempt to prevent the spread of the virus and boost the immune system of a Ugandan doctor who has contracted Ebola. As you probably know, the deadly disease is one of the hottest topics on the stock markets and, not surprisingly, the news had a major effect on AEMD's performance.
Advertisement
In a matter of just six and a half hours the ticker managed to gain as much as 66% and it even hit a 52-week high of more than $0.30 per share. Investors were extremely excited about the application of the blood filtration device and it wasn't long before some outfits and newsletters were also jumping up and down and waving their arms about. The general notion that the two outfits wanted to convey is that the use of AEMD's Hemopurifier in the battle against Ebola could open up numerous opportunities for the company.
An analyst brief which covers a brief technical analysis and analyst recommendation can be viewed in its entirety by using the link below. There is no cost obligation required to view this report:
http://bit.ly/-AEMD-AnalystReport
Copy and paste to browser may be required.
Forward-Looking Disclaimer
This report may contain certain forward-looking statements and information, as defined within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, and is subject to the Safe Harbor created by those sections. This material contains statements about expected future events and/or financial results that are forward-looking in nature and subject to risks and uncertainties. Such forward- looking statements by definition involve risks, uncertainties and other factors, which may cause the actual results, performance or achievements of mentioned company to be materially different from the statements made herein.
Not Financial Advice
BrokerBank Securities, Inc. make no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.
Compliance Procedure
Content is researched, written and reviewed on a best-effort basis by a 3rd party research analyst. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below. We do not engage in high frequency trading.
A full disclaimer can be found by viewing the analyst report.
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
BrokerBank Securities, Inc. is a member of the Financial Industry Regulatory Authority, CRD number #130116.
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/aethlon-medical-analyst-coverage-initiated-against-ebola-stock-crash-by-brokerbank-securities-inc-788427020.html
SOURCE BrokerBank Securities, Inc.
